Seedlabs

IL-36 Psoriasis Biologic Selection Panel

A blood or skin test to help doctors choose the right biologic medicine for psoriasis patients.

A blood or skin-lesion test measuring IL-36α, IL-36β, and IL-36γ to classify psoriasis patients as 'IL-36-driven,' guiding selection between anti-IL-17, anti-IL-23, and anti-IL-36R biologic therapies.

Biochemistry, Genetics and Molecular BiologyInflammasome and immune disorders
Metabolism and Genetic DisordersDermatology precision-medicine diagnostic for psoriasis biologic selection

Concept

A multiplexed immunoassay (ELISA or Luminex) measuring the three IL-36 agonist cytokines in either serum or a small skin-lesion biopsy from a psoriasis patient. Patients with elevated IL-36 are classified as having the "IL-36-driven" subtype, which the paper shows operates upstream of the IL-23/IL-17/IL-22 cascade. Dermatologists currently choose biologics by trial-and-error at $30,000–$75,000 per year; this panel gives them a mechanistic basis to pick the right drug class first — IL-36-high patients may respond preferentially to IL-36R blockade or upstream pathway inhibition, while IL-36-low patients may do better on downstream IL-17 or IL-23p19 inhibitors.

Why now

The paper demonstrates that IL-36 cytokines induce IL-23, IL-17, and IL-22, contributing to psoriasis and other neutrophilic skin disorders. This positions IL-36 as an identifiable upstream driver of the psoriasis cytokine cascade. With multiple biologic classes now approved for psoriasis (anti-IL-17, anti-IL-23p19, anti-IL-36R for pustular variants) and response rates varying widely between patients, a biomarker that predicts the dominant pathway is commercially valuable to payers, dermatologists, and patients who currently cycle through ineffective drugs for months.

Written by GLM · 11 Oct 2026

AI assessment

Backed by 1 paper89

A high-value precision medicine tool that leverages a clear upstream mechanistic driver to reduce the costly trial-and-error cycle of psoriasis biologics.

Evidence strength
4/5
The research explicitly states that IL-36 cytokines induce the IL-23/IL-17/IL-22 cascade, providing a strong mechanistic basis for using IL-36 as a predictive biomarker for drug selection.
Market pull
5/5
The high cost of biologics ($30k-$75k/year) and the prevalence of non-responders create an urgent economic incentive for payers and clinicians to optimize first-line selection.
Novelty & moat
4/5
While other cytokine tests exist, applying the IL-36 upstream driver specifically to differentiate between IL-17, IL-23, and IL-36R therapies is a distinct and novel clinical application.
Feasibility
5/5
Multiplexed immunoassays (ELISA/Luminex) are mature technologies, making the transition from the research finding to a clinical prototype straightforward.
Wedge clarity
4/5
The focus on 'IL-36-driven' classification for biologic selection is a sharp, specific entry point into the dermatology market.
Simplicity / focus
5/5
The idea is a single, focused diagnostic panel with one clear purpose, avoiding the pitfalls of an over-scoped platform.

Scored by Gemma 4 · 11 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Boehringer Ingelheimcompany

    Boehringer Ingelheim developed spesolimab (anti-IL-36R) for generalized pustular psoriasis; an IL-36 biomarker panel could expand their drug's use into the broader psoriasis market by identifying responsive patients.

  • National Psoriasis Foundationorganization

    The NPF advocates for faster access to effective treatment; a test that reduces months of ineffective biologic cycling directly serves their patient community's interests.

  • AbbViecompany

    AbbVie markets Skyrizi (anti-IL-23) and previously Humira for psoriasis; a pathway-selection test could improve their drug positioning and reduce costly trial-and-error switching.

  • Amgencompany

    Amgen has a dermatology portfolio (Otezla, Tezspire) and could use IL-36 stratification to position existing or pipeline products for the right patient subgroup.

Research it builds on

  1. IL-1 family cytokines in inflammation and immunity
    Cecília Garlanda, Irene Di Ceglie, Sébastien Jaillon · 2025 · 123 citations
    All ideas from this paper →
Leave feedback
feasibility